389 related articles for article (PubMed ID: 22015292)
1. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
Giuliano M; Schifp R; Osborne CK; Trivedi MV
Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
[TBL] [Abstract][Full Text] [Related]
2. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer.
Arpino G; De Angelis C; Giuliano M; Giordano A; Falato C; De Laurentiis M; De Placido S
Oncology; 2009; 77 Suppl 1():23-37. PubMed ID: 20130429
[TBL] [Abstract][Full Text] [Related]
4. New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK; Marquez-Garban DC; Pietras RJ
Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
[TBL] [Abstract][Full Text] [Related]
5. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
6. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
Nahta R; O'Regan RM
Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
[TBL] [Abstract][Full Text] [Related]
8. New strategies in estrogen receptor-positive breast cancer.
Johnston SR
Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
10. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
11. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
12. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of tamoxifen resistance.
Ring A; Dowsett M
Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
[TBL] [Abstract][Full Text] [Related]
14. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
17. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
18. Resistance to endocrine therapy in breast cancer.
Kurebayashi J
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():39-46. PubMed ID: 16273353
[TBL] [Abstract][Full Text] [Related]
19. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
Roop RP; Ma CX
Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
[TBL] [Abstract][Full Text] [Related]
20. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
